---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-029167"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T21:13:28.684508+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru reports Q1 FY2023 net loss of $36.8M; revenue falls 82% to $2.5M

## Summary
- Net revenues decreased to $2.5M from $14.1M in prior-year quarter; gross profit fell to $0.7M.
- Net loss of $36.8M ($0.46 per share) vs. $6.4M ($0.08) a year ago; operating loss $35.6M.
- Cash and equivalents dropped to $46.9M at Dec 31, 2022 from $80.2M at Sep 30, 2022.
- Sabizabulin for COVID-19 under review by FDA, EMA, MHRA, TGA, Health Canada and others.
- IDWeek data: sabizabulin showed 81.2% relative reduction in deaths in WHO 4 subset (p=0.0090).

## SEC filing metadata
- accession: 0001193125-23-029167
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/0001193125-23-029167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/d458190d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-029167
- JSON: https://secwatch.observer/filing/0001193125-23-029167.json
- Plain text: https://secwatch.observer/filing/0001193125-23-029167.txt

## Key facts
- Earnings Releases
  VERU INC. reported fiscal 2023 first quarter results: revenue $2.5 million, net income $36.8 million, or $0.46 per share.
  - Period: fiscal 2023 first quarter
  - Revenue: $2.5 million
  - Net income: $36.8 million, or $0.46 per share
  - Result: reported results
  source text: with an enlarged prostate experiencing the signs and symptoms of BPH for up to 26 weeks. First Quarter Financial Summary: Fiscal 2023 vs Fiscal 2022 • Net revenues decreased to $2.5 million from $14.1 million • Gross profit decreased to $0.7 million from $11.8 million 2 • Research and development expenses increased to $18.7 million from $10.1 million • Selling,
  evidence_url: https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/0001193125-23-029167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.